Novel Food Toxicity Testing: Regulatory Framework, Test Battery, and Evaluation Methods

Novel food toxicity testing is the scientific cornerstone for demonstrating that ingredients without a customary history of consumption are safe for human intake. This technical guide explains the tiered toxicological evaluation framework—covering acute toxicity, genotoxicity, subchronic, chronic, and reproductive studies—governed by China's GB 15193 standard series and aligned with international OECD Test Guidelines. Learn which studies apply to your novel food ingredient, how they are conducted, and what data regulators expect before market approval.

Technical Overview

Novel foods—designated in China as novel food ingredients—are substances without a significant history of human consumption within a jurisdiction, including new plants, animals, microorganisms, extracts from conventional foods, and new molecular or structural forms of existing nutrients. Because a long record of safe use cannot be invoked, regulators require a systematic toxicological evaluation before these ingredients may enter the food supply.

In China, the safety review of novel food ingredients is administered by the National Health Commission (NHC) under the Administrative Measures for the Safety Review of Novel Food Ingredients. The technical basis for evaluation is the GB 15193 series, the national food safety standards covering procedures and test methods for toxicological assessment of food safety. Comparable frameworks exist internationally, including Regulation (EU) 2015/2283 in the European Union and the GRAS system in the United States, with study designs broadly harmonized through OECD Test Guidelines and WHO/FAO risk assessment principles.

Toxicity testing follows a tiered, weight-of-evidence strategy that progresses from short-term screening to long-term studies only when warranted. The core stages are:

• Stage one: acute oral toxicity testing combined with a genotoxicity screening battery.
• Stage two: subchronic repeat-dose studies (typically 90 days) and reproductive or developmental toxicity testing.
• Stage three: chronic toxicity and carcinogenicity studies for ingredients with significant exposure or positive earlier findings.
• Supplementary studies: toxicokinetics, metabolism, allergenicity assessment, and mechanistic investigations as needed.

The ultimate outputs of the program are hazard identification, derivation of a No-Observed-Adverse-Effect Level (NOAEL), calculation of an Acceptable Daily Intake (ADI) using an uncertainty factor typically set at 100, and a comparison of the ADI with estimated human dietary exposure.

Testing Samples

Novel Botanical, Zoological, and Algal Ingredients

This category covers plants, animals, insects, and algae not traditionally consumed as food in the target market, such as exotic fruits, novel seaweeds, insect-derived protein powders, and algal biomass. Testing focuses on inherent toxicity, natural toxin carryover, and contaminants introduced by cultivation or processing.

Novel Microorganisms and Fermentation Products

New bacterial and fungal strains intended for direct consumption, including probiotic cultures and production organisms, require toxicity testing together with strain identification, pathogenicity assessment, and antibiotic resistance profiling. Fermentation-derived ingredients must also be evaluated for residual metabolites and production organism DNA.

Concentrated Extracts and Isolates from Conventional Foods

When bioactive compounds are extracted and concentrated from foods with a customary history of use, the resulting exposure may far exceed normal dietary levels. Examples include plant sterols, polyphenol concentrates, and protein hydrolysates, which require repeat-dose testing to characterize dose-response effects.

New Molecular and Structural Forms

Synthetic or biotechnologically produced nutrients, structured lipids, engineered peptides, novel oligosaccharides, and new crystal or isomeric forms of known substances fall under this category. Testing emphasizes comparative toxicology against the parent compound, absorption and metabolism studies, and impurity characterization.

Testing Items

A typical novel food toxicity dossier includes the following study types, with the exact battery determined by the nature of the ingredient, anticipated exposure, and available scientific literature:

• Acute oral toxicity testing (LD50 or maximum tolerated dose determination).
• Genotoxicity battery: bacterial reverse mutation assay (Ames test), in vitro mammalian chromosomal aberration assay, and mammalian erythrocyte micronucleus test.
• Repeat-dose toxicity: 28-day and 90-day subchronic studies in rodents, with non-rodent studies when indicated.
• Reproductive toxicity, developmental and teratogenicity testing.
• Chronic toxicity and carcinogenicity studies, often conducted as a combined assay.
• Toxicokinetic and metabolism studies describing absorption, distribution, biotransformation, and excretion.
• Supporting assessments: in vitro digestibility and protein allergenicity screening, stability testing, and contaminant analysis.

Testing Methods

Acute Oral Toxicity

Single-dose oral administration, generally by gavage, is followed by a 14-day observation period with mortality, clinical signs, body weight, and gross pathology recording. A limit test at 2000–5000 mg/kg body weight is applied when low toxicity is expected. Studies follow GB 15193.3 and OECD Test Guidelines 423 or 425, with dosing schemes such as the acute toxic class or up-and-down procedure to minimize animal use while estimating the LD50.

Genotoxicity Assays

The bacterial reverse mutation assay (GB 15193.4, OECD TG 471) employs at least five Salmonella typhimurium strains, with and without S9 metabolic activation, using plate incorporation and preincubation protocols with appropriate positive and negative controls. The in vitro chromosomal aberration assay (GB 15193.6, OECD TG 473) uses mammalian cell lines such as CHL, CHO, or V79 under short and extended exposure conditions, while the micronucleus test (GB 15193.5, OECD TG 474) examines bone marrow polychromatic erythrocytes in rodents at two sampling times. A positive finding triggers additional assays, such as the mouse lymphoma TK gene mutation test, for weight-of-evidence conclusions.

Subchronic Repeat-Dose Studies

The 90-day oral toxicity study (GB 15193.8, OECD TG 408) administers at least three dose levels plus a control group, typically to 10–20 animals per sex per group, via gavage or dietary admixture. Endpoints include survival, clinical observations, body weight, food consumption, functional tests, ophthalmology, hematology, clinical chemistry, urinalysis, organ weights, gross necropsy, and full histopathology. The high dose should elicit toxicity without severe distress, and a limit dose of 1000 mg/kg body weight per day is acceptable unless human exposure is substantially higher. The principal deliverable is identification of target organs and the NOAEL.

Reproductive and Developmental Toxicity